Windlas Biotech Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/uwizwc3pupyjo7l7zi6v8xjb.pdf

Key Takeaways


CDMO: The Growth Engine

Hitesh Windlass: "My instinct is to say that this is a credit to the team rather than credit to API prices."

Trade Generics: Reshaping After the Codeine Shock

Hitesh Windlass: "Does codeine define trade generics, or is the requirement for medicines and the gap of access to quality medicines remain fundamentally there, regardless of one particular SKU being impacted?"

Exports & EU GMP: The Injectables Opportunity

Hitesh Windlass: "I can sort of state that we are executing towards that goal, and I'm very glad to share that we have been successful in our first attempt with EU GMP for injectables."

Capacity, Capex & Capital Allocation

Komal Gupta: "Because we have liquidity, we want to put the money somewhere is not how we think about it. How we think about is having enough, number one. Number two is in terms of strategy of how to spend the money is very clear."

Margins: The Step-Up and What Comes Next

Komal Gupta: "Consistency is not the most exciting word in business, but it is the one our customers and shareholders value the most."

Guidance & Commitments

CommitmentSpecificsTimeline
Trade generics recoveryGrowth to resume to pre-codeine event numbers, potentially moreFY28 (aspiration)
Capacity ceilingExisting facilities can serve up to ₹1,100 crores company-level, with up to 10% improvement possibleCurrent state
New oral solids capacityPhase-wise build starts when existing facilities approach peakTrigger-based, no date
Opex reduction projectCapex of ₹25–30 crores, expected to reduce opex by similar magnitude"Coming quarters" (vague)
EU injectables revenueProduct-wise approvals follow plant approval; internal expectations exist but not sharedDependent on regulator
New dosage formActively looking for acquisition; if none finalized, may build internally; nothing initiated yetNo timeline
Capital allocationPriority order: acquisition, core capex, internal new dosage form, buyback, dividend, employee rewardsOngoing philosophy
BuybackCompleted ₹47 crores without promoter participation; future buybacks if market price is much lower than intrinsic valueCondition-based

Key Metrics

MetricQ2 FY27
Revenue₹264 cr, +19% YoY
H1 FY27 revenue₹512 cr, +18% YoY; first time crossing ₹500 cr half-yearly
Generic formulation CDMO revenue₹215 cr, +34% YoY
Trade generics & institutional revenue₹36 cr
Exports revenue₹12 cr, +26% YoY
EBITDA (excl. ESOP)₹36 cr, 13.7% margin; improved from historical 11–12%
PAT (excl. ESOP)₹25 cr, 9.5% margin
Reported EBITDA₹29 cr
Reported PAT₹18 cr
H1 FY27 EPS₹17.21, highest-ever
ROCE28%
ROE24%
Net liquidity (H1 FY27 close)₹223 cr
Indian pharma market volume growth2.5% during the quarter
Plant 6 commercializationSeptember 28, 2026; costs flow to Q3
Opex reduction project capex planned₹25–30 cr